Phase 4
Completed N=43
Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics
Source: ClinicalTrials.gov NCT01386970 ↗Enrolled (actual)
43
Serious AEs
0.0%
Results posted
Mar 2020
Primary outcomePrimary: ZDV-TP Drug Levels Compared Between HIV Negative and HIV Infected Subject — 33.89; 29.7 pmol/10^6 cells
◆ Published Evidence
Established
31citations · ~2 / year
Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults.
Summary
This study evaluated the blood and blood cell concentrations of zidovudine and lamivudine in men versus women and in those with versus without HIV infection. Additionally, markers of side effects were correlated with blood levels of the drugs. The hypothesis was that women and those with HIV would have higher drug levels, as well as markers of side effects.
Linked Publications (3)
-
Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults.
-
Validation of a sensitive LC/MS/MS method for the determination of zidovudine and lamivudine in human plasma.
-
Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY ZDV-TP Drug Levels Compared Between HIV Negative and HIV Infected Subject |
33.89; 29.7 | — |
| PRIMARY 3TC-TP Drug Levels Compared Between HIV Negative and HIV Infected Subject |
7.25; 5.3 | — |
Eligibility Criteria
Inclusion Criteria
- Documented physician-diagnosed HIV-infection (HIV+ antibody or plasma HIV-RNA+); HIV-negative volunteers must have a negative HIV-ELISA.
- Age 18 to 55 years;
- Either antiretroviral naïve, or no HIV-therapy in the preceding 6 months;
- Planned antiretroviral regimen includes standard doses of ZDV plus 3TC as part of the antiretroviral regimen. Once- or twice-daily 3TC will be allowed.
Exclusion Criteria
- Any medical condition that in the opinion of the investigators would jeopardize the intent of the study.
- In the opinion of the investigator, any concomitant immunomodulatory medications, chemotherapeutic agents, investigational drugs, and alternative therapies, including, glucocorticoids, recombinant growth factors or cytokines (e.g. Granulocyte-macrophage colony-stimulating factor, Granulocyte colony-stimulating factor, interferon-alpha or gamma, human growth hormone, etc), ribavirin, birth-control pills, and sex hormones that could interfere with the cellular pharmacology of the study medications;
- Concomitant medications that interfere with renal drug clearances including, tenofovir, adefovir, cidofovir, ganciclovir, probenecid, or any similarly problematic medication in the opinion of the investigators;
- Concomitant warfarin or daily aspirin (to prevent excess bleeding from biopsy).
- Pregnancy or a plan to become pregnant, or menopause;
- Any > or = grade II abnormality in hemoglobin, absolute neutrophil count, routine liver function tests, serum creatinine, or other organ function abnormalities.
- Any medical or personal condition that, in the judgment of the investigators, may influence the subject's ability to comply with study conditions, such as active mental illnesses, or plans to leave the geographical area.
- Inability to give informed consent.
- Triple nucleoside analog reverse transcriptase regimens.
Data sourced from ClinicalTrials.gov (NCT01386970) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.